ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1586 • ACR Convergence 2022

    Sustained Remission Following the Discontinuation of Tofacitinib in Patients with Rheumatoid Arthritis (XANADU Study): A Multicenter, Prospective, and Randomized Controlled Study

    Satoshi Kubo1, Yusuke Miyazaki2, Koichi Amano3, Kiyoshi Matsui4, Hideto Kameda5, Yoshino Inoue6, Shingo Nakayamada6, Takehisa Ogura7, Yuko Kaneko8, Kunihiro Yamaoka9 and Yoshiya Tanaka10, 1Department of Advanced Targeted Therapies, University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, 2The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kiakyusyu Fukuoka, Japan, 3Saitama Medical Center, Kawagoe, Japan, 4Hyogo College of Medicine, Nishinomiya, Japan, 5Toho University, Tokyo, Japan, 6First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, 7Toho university, Meguro-ku, Japan, 8Keio University, Tokyo, Japan, 9Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, 10University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan

    Background/Purpose: To investigate sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (RA).Methods: RA patients who had an inadequate response to methotrexate…
  • Abstract Number: 1600 • ACR Convergence 2022

    The Impact of Second-Line Therapeutic on Disease Control After Discontinuation of First Line TNF Inhibitor in Patients with PsA: Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

    Alexis Ogdie1, Robert McLean2, Taylor Blachley2, Nicole Middaugh2, Manish Mittal3, Jerry Clewell3, Sandra Ciecinski4 and Philip J Mease5, 1Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2CorEvitas, LLC, Waltham, MA, 3AbbVie, Inc., North Chicago, IL, 4AbbVie, Inc., Mettawa, IL, 5Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

    Background/Purpose: While evidence in patients (pts) with RA suggests that switching to a therapy with a different mechanism of action (MOA) may be more effective…
  • Abstract Number: 1602 • ACR Convergence 2022

    Fibroblast Activation Protein (FAP) PET-CT for Depicting Inflammatory Joint Damage in Patients with Psoriatic Arthritis

    Simon Rauber1, Hashem Mohammadian2, Chrstian Schmidkonz3, Armin Atzinger3, Maria Gabriella Raimondo1, Hannah Labinsky4, Christoph Treutlein2, Johannes Knitza1, Simone Maschauer2, Frank Roemer5, Olaf Prante2, Torsten Kuwert3, Juan Canete6, Georg Schett7 and Andreas Ramming1, 1Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 2Friedrich-Alexander-University (FAU) Erlangen-Nürnberg, Erlangen, Germany, 3Friedrich-Alexander University (FAU) Erlangen-Nuremberg, Erlangen, Germany, 4Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 5Friedrich-Alexander University Erlangen Nürnberg, Erlangen, Germany, 6Unidad de Artritis Hospital Clinic, Barcelona, Spain, 7Universitätsklinikum Erlangen, Erlangen, Germany

    Background/Purpose: Psoriatic arthritis (PsA) is characterized by substantial mesenchymal tissue activation in the context of inflammation leading to structural damage. Measuring mesenchymal tissue activation in…
  • Abstract Number: 1601 • ACR Convergence 2022

    Female Psoriatic Arthritis Patients Show Differences in Treatment Response to IL12/23 Inhibition in Combination with or Without MTX Compared to Male – Results from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical Trial

    Michaela Koehm1, Ann Christina Foldenauer2, Tanja Rossmanith3, Herbert Kellner4, Uta Kiltz5, Juergen Rech6, Gerd Burmester7, David Kofler8, Jan Brandt-Juergens9, Stephanie Finzel10, Raoul Bergner11, Maren Sieburg12 and Frank Behrens13, 1Rheumatology Goethe-University Frankfurt, Frankfurt Am Main, Germany, 2Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, 3Fraunhofer Institute for Translational Medicine & Pharmacology ITMP, Frankfurt, Germany, 4Schwerpunktpraxis für Rheumatologie und Gastroenterologie, Munich, Germany, 5Rheumazentrum Ruhrgebiet, Herne, Germany, 6University Clinic Erlangen, Erlangen, Germany, 7Charité University Medicine Berlin, Berlin, Germany, 8University of Cologne, Cologne, Germany, 9Rheumatologische Schwerpunktpraxis, Berlin, Germany, 10University of Freiburg, Freiburg, Germany, 11Klinikum Ludwigshafen, Ludwigshafen, Germany, 12Rheumatologische Facharztpraxis, Magdeburg, Germany, 13Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany

    Background/Purpose: Subgroup analysis from different clinical trials and real-world data suggest, that there are differences in baseline characteristics, clinical phenotypes, and treatment responses in female…
  • Abstract Number: 1554 • ACR Convergence 2022

    Serum Biomarkers in Association with Clinical and Vascular Disease Activity in Takayasu’s Arteritis

    Cameron Rankin1, Peter Grayson2, Bates Gribbons3, Kaitlin Quinn4, Christopher Redmond5 and Wanxia Tsai1, 1NIAMS/NIH, Bethesda, MD, 2National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 3McGovern Medical School, Colleyville, TX, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, 5National Institutes of Health, Rockville, MD

    Background/Purpose: 18FDG-PET imaging can be used to directly assess vascular inflammation; however, limited access to this technology has restricted widespread adoption of this modality in…
  • Abstract Number: 1584 • ACR Convergence 2022

    Colchicine or Prednisone for the Treatment of Acute Calcium Pyrophosphate Deposition Arthritis: A Multicenter Randomized Controlled Trial

    Tristan Pascart1, Pierre Robinet2, Sebastien Ottaviani3, Remi Leroy4, Nicolas Segaud5, Aurore Pacaud2, Hélène Luraschi2, Thibault Rabin2, Agathe Grandjean2, Xavier Deplanque6, Pierre Maciejasz6, Fabien Visade2, Alexandre Mackowiak2, Nicolas Baclet6, Antoine Lefebvre2, Jean-François Budzik2, Thomas Bardin7, Pascal Richette8, Laurène Norberciak2, Vincent Ducoulombier2 and Eric Houvenagel1, 1Groupement Hospitalier de l'Institut Catholique de Lille, Lomme, France, 2Hôpital Saint-Philibert, Lomme, France, 3Hopital Bichat-Claude Bernard, Paris, France, 4Centre Hospitalier de Dunkerque, Dunkerque, France, 5Centre Hospitalier d'Armentières, Armentières, France, 6Hôpital Saint-Vincent-de-Paul, Lille, France, 7Hôpital Lariboisiere, Paris, France, 8Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France

    Background/Purpose: Treatment of acute CPP arthritis mainly relies on expert opinion, as there are no trials that assessed the efficacy of anti-inflammatory drugs, despite the…
  • Abstract Number: 1610 • ACR Convergence 2022

    Are Serological Protease-mediated Peptides of Tissue Remodeling and Inflammation the New Disease Activity Biomarkers in Psoriatic Arthritis Patients?

    Solveig S. Groen1, Signe Holm Nielsen2, Anne-Christine Bay-Jensen2, Mozhgan Rasti3, Darshini Ganatra3, Katerina Oikonomopoulou3 and Vinod Chandran4, 1Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark, 2Nordic Bioscience, Herlev, Denmark, 3Schroeder Arthritis Institute, Krembil Research Institute, Toronto, ON, Canada, 4Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada

    Background/Purpose: Inflammatory and degenerative processes in the joint tissues are hallmarks of patients with psoriatic arthritis (PsA). Here, proteases play a major role in remodeling…
  • Abstract Number: 1592 • ACR Convergence 2022

    Serious Infections in SLE- Incidence, Associated Factors, Impact and Trends over Two Decades

    Rudrarpan Chatterjee, Sarit Sekhar Pattanaik, Durga P Misra, Vikas Agarwal, Able Lawrence and Amita Aggarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

    Background/Purpose: Infections are a major cause of morbidity and mortality in systemic lupus erythematosus (SLE). We assessed the incidence and risk factors for major infections…
  • Abstract Number: 1617 • ACR Convergence 2022

    Direct Comparison of Ultrasound, [18F]Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging: Early Diagnostics in Patients Suspected of Giant Cell Arteritis

    Marieke van Nieuwland1, Marloes Vermeer1, Edgar Colin2, Nils Wagenaar1, Onno Vijlbrief1, Jordy van Zandwijk3, Riemer Slart4, Hendrik Koffijberg3, Erik Groot Jebbink3, Elisabeth Brouwer4, Dennis Boumans1 and Celina Alves1, 1Hospital Group Twente, Almelo, Netherlands, 2Hospital Group Twente, Deventer, Netherlands, 3University of Twente, Enschede, Netherlands, 4University Medical Center Groningen, Groningen, Netherlands

    Background/Purpose: Giant cell arteritis (GCA) requires rapid diagnostic work up and start of treatment to prevent severe complications. The temporal artery biopsy as a gold…
  • Abstract Number: 1618 • ACR Convergence 2022

    Combined Orbital and Cranial Vessel Wall MRI for Diagnosis and Longitudinal Monitoring of Giant Cell Arteritis

    Rennie Rhee, Shubhasree Banerjee, Vatsal Bhatt, Madhura Tamhankar, Quy Cao, Naomi Amudala, Sherry Chou, Morgan Burke, Laurie Loevner, Peter Merkel and Jae Song, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: In giant cell arteritis (GCA), there is a critical need to identify patients at risk for vision loss ("ocular GCA"). MRI evaluates neurovascular anatomy…
  • Abstract Number: 1611 • ACR Convergence 2022

    Putative Role of the Histidine and Tryptophan Biochemical Pathways in the Mode of Action of Upadacitinib in Patients with Ankylosing Spondylitis

    Thierry Sornasse1, Liang Li2, Shuang Zhao2, Xiaohang Wang2, Fang Cai3, Yingtao Bi4, In-Ho Song5, Stephanie Wichuk6, Robert G. Lambert7 and Walter P Maksymowych8, 1AbbVie, South San Francisco, CA, 2The Metabolomics Innovation Centre and Department of Chemistry, University of Alberta, Edmonton, AB, Canada, 3AbbVie, Redwood City, CA, 4AbbVie, Inc, Worcester, MA, 5AbbVie, Inc., North Chicago, IL, 6University of Alberta, Edmonton, AB, Canada, 7Department of Medicine, Division of Rheumatology, University of Alberta, Edmonton, AB, Canada, 8Department of Medicine, University of Alberta, Edmonton, AB, Canada

    Background/Purpose: Upadacitinib (UPA) 15 mg QD is efficacious in patients with active ankylosing spondylitis (AS) exhibiting inadequate responses to nonsteroidal anti-inflammatory drugs (NSAIDs-IR).1 We determined…
  • Abstract Number: 1625 • ACR Convergence 2022

    Single Cell and Spatial Transcriptomics Identifies Pathogenic Drivers of Sjogren’s Disease in Humans

    Blake Warner1, Thomas Pranzatelli2, Paola Perez2, Daniel Martin2, Shyh-Ing Jang2, Kalie Dominick2, Eiko Yamada2, Kevin Byrd3, Quinn Easter4, A. Darise Farris5, Christopher Lessard5, Amanda Oliver6, Raquel Bartolome-Casado6, Zohreh Khavandgar1, Sarthak Gupta7, Sarah Teichmann6, Alan Baer8 and John Chiorini2, 1National Institutes of Health, Bethesda, MD, 2NIDCR, Bethesda, MD, 3American Dental Association, Scientific Research Institute, Gaithersburg, MD, 4American Dental Association, Gaithersburg, MD, 5Oklahoma Medical Research Foundation, Oklahoma City, OK, 6Wellcome Sanger Institute, Cambridgeshire, United Kingdom, 7National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 8Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Sjogren's Disease(SjD) is a systemic autoimmune disease characterized by exocrine dysfunction. The pathogenesis is incompletely understood, but involves gene-environment interactions leading to infiltration of…
  • Abstract Number: 1626 • ACR Convergence 2022

    Unique Biological Profile of Germinal Centres Within Tertiary Lymphoid Structures in the Salivary Glands of Patients with Sjögren’s Syndrome

    SABA NAYAR1, Jason D. turner1, Saba Asam1, Serena Colfrancesco2, Onorina Berardicurti3, Valentina Iannizzotto1, Charlotte G Smith1, Joe Flint1, Ana Teodósio1, David H Gardner1, Professor Simon Bowman4, Wan-Fai Ng5, Adam Croft1, Andrew Filer1, Benjamin A. Fisher1, Christopher Buckley6 and Francesca Barone7, 1University of Birmingham, Birmingham, United Kingdom, 2University of Rome, Rome, Italy, 3Rheumatology Unit, Pescara Hospital, Pescara, Italy, 4University Hospitals Birmingham, Birmingham, United Kingdom, 5Newcastle University, Newcastle, United Kingdom, 6University of Oxford, Oxford, United Kingdom, 7University of Birmingham, Needham, MA

    Background/Purpose: Tertiary lymphoid structures (TLS) are accumulations of lymphoid cells that share similar cellular compartments, organization and function when compared to secondary lymphoid organs (SLOs)…
  • Abstract Number: 1632 • ACR Convergence 2022

    Novel Autoantibodies Identify Sjögren’s Disease in Patients Lacking Serum IgG Specific for Ro/SS-A and La/SS-B

    Sherri Longobardi1, Charmaine Lopez-Davis1, Bhuwan Khatri1, Constantin Georgescu1, Christina Lawrence1, Astrid Rasmussen1, Lida Radfar2, R. Hal Scofield2, Robert C. Axtell1, Gabriel Pardo1, Jonathan Wren1, Kristi A Koelsch1, Joel Guthridge1, Judith James1, Christopher Lessard1 and A. Darise Farris1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Oklahoma Health Sciences Center, Oklahoma City, OK

    Background/Purpose: Classification of Sjögren's disease (SjD) requires either Ro/SS-A autoantibodies or minor salivary gland biopsy positive for focal lymphocytic infiltrates. Up to 40% of SjD…
  • Abstract Number: 1624 • ACR Convergence 2022

    Blocking IL-1, IL-33 and IL-36 Signaling with the Anti-IL1RAP Antibody mCAN10 Ameliorates Inflammation and Fibrosis in Preclinical Models of Systemic Sclerosis

    Caitriona Grönberg1, Sara Rattik1, Meik Kunz2, Thoung Trinh-Minh3, Cuong Tran-Manh3, Xiang Zhou3, Petter Skoog1, David Liberg1 and Jörg Distler3, 1Cantargia AB, LUND, Sweden, 2Friedrich-Alexander University (FAU) Erlangen-Nuremberg, Erlangen, Germany, 3Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany

    Background/Purpose: The IL-1 receptor accessory protein (IL1RAP) is a co-receptor required for signaling through the IL-1, IL-33, and IL-36 receptors. IL1RAP-dependent signaling has been implicated…
  • « Previous Page
  • 1
  • …
  • 439
  • 440
  • 441
  • 442
  • 443
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology